tbuckley/cabot-search huggingface dataset:
Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
Authors: Ruben Mesa, Catriona Jamieson, Ravi Bhatia, Michael W. Deininger, Aaron T. Gerds, Ivana Gojo, Jason Gotlib, Krishna Gundabolu, Gabriela Hobbs, Rebecca B. Klisovic, Patricia Kropf, Sanjay R. Mohan, Stephen Oh, Eric Padron, Nikolai Podoltsev, Daniel A. Pollyea, Raajit Rampal, Lindsay A. M. Rein, Bart Scott, David S. Snyder, Brady L. Stein, Srdan Verstovsek, Martha Wadleigh, Eunice S. Wang, Mary Anne Bergman, Kristina M. Gregory, Hema Sundar
Journal: Journal of the National Comprehensive Cancer Network (2016)

Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are a group of heterogeneous disorders of the hematopoietic system collectively known as Philadelphia chromosome–negative myeloproliferative neoplasms (MPNs). The diagnosis and the management of patients with MPNs have evolved since the identification of mutations that activate the JAK pathway (JAK2, CALR, and MPL mutations) and the development of targeted therapies has resulted in significant improvements in disease-related symptoms and quality of life. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnostic workup of MPN (MF, PV, and ET), risk stratification, treatment, and supportive care strategies for the management of MF.
Melphalan/Prednisone/Lenalidomide (MPR) Versus High-Dose Melphalan and Autologous Transplantation (MEL200) in Newly Diagnosed Multiple Myeloma (MM) Patients &lt;65 Years: Results of a Randomized Phase III Study
Authors: Antonio Palumbo, Federica Cavallo, Izhar Hardan, Barbara Lupo, Valter Redoglia, Moshe Levin, Paolo Corradini, Sara Pezzatti, Francesca Patriarca, Michele Cavo, Magda Marcatti, Norbert Pescosta, Antonietta Pia Falcone, Roberto Ria, Davide Rossi, Giulia Benevolo, Clotilde Cangialosi, Monica Galli, Lucio Catalano, Anna Baraldi, Angelo Michele Carella, Annamaria Cafro, Agostina Siniscalchi, Claudia Crippa, Sara Grammatico, Maide Cavalli, Tommaso Caravita Di Toritto, Francesco Di Raimondo, Arnon Nagler, Mario Boccadoro
Journal: Blood (2011)
TAOK2 Kinase Mediates PSD95 Stability and Dendritic Spine Maturation through Septin7 Phosphorylation
Authors: Smita Yadav, Juan A. Oses-Prieto, Christian J. Peters, Jing Zhou, Samuel J. Pleasure, Alma L. Burlingame, Lily Y. Jan, Yuh-Nung Jan
Journal: Neuron (2017)

Abnormalities in dendritic spines are manifestations of several neurodevelopmental and psychiatric diseases. TAOK2 is one of the genes in the 16p11.2 locus, copy number variations of which are associated with autism and schizophrenia. Here, we show that the kinase activity of the serine/threonine kinase encoded by TAOK2 is required for spine maturation. TAOK2 depletion results in unstable dendritic protrusions, mislocalized shaft-synapses, and loss of compartmentalization of NMDA receptor-mediated calcium influx. Using chemical-genetics and mass spectrometry, we identified several TAOK2 phosphorylation targets. We show that TAOK2 directly phosphorylates the cytoskeletal GTPase Septin7, at an evolutionary conserved residue. This phosphorylation induces translocation of Septin7 to the spine, where it associates with and stabilizes the scaffolding protein PSD95, promoting dendritic spine maturation. This study provides a mechanistic basis for postsynaptic stability and compartmentalization via TAOK2-Sept7 signaling, with implications toward understanding the potential role of TAOK2 in neurological deficits associated with the 16p11.2 region.
P2.03b-071 Therapeutic Targeting of the Phosphatidylinositol-3 Kinase Pathway in Lung Squamous Cell Carcinoma
Authors: Ruoshi Shi, Ming Li, Michael Cabanero, Nhu-An Pham, Christine Ng, Frances Shepherd, Nadeem Moghal, Ming Tsao
Journal: Journal of Thoracic Oncology (2017)
Co-Overexpression of YY1 and Gp-170 (MDR1) in Childhood Acute Lymphocytic Leukemia (ALL): Transcription Regulation of Gp-170 by YY1 and Prognostic Significance,
Authors: Gabriela andres-Antonio, Jesus Rangel-Santiago, Ana B Tirado-Rodriguez, Elisa Dorantes-Acosta, Mario I Vega, Guillermo Aquino-Jarquin, Briseida Lopez, Elba Jimenez, Rosana Pelayo, Benjamin Bonavida, Aurora Medina-Sanson, Sara Huerta-Yepez
Journal: Blood (2011)
P149 Designing a management plan: a mixed methods approach to exploring patient journeys in children with severe and recurrent wheeze
Authors: SB Naidu, R Kerr, M Kecman, R Klaber
Journal: Thorax (2016)

<h3>Introduction</h3> Management plans, while recommended nationally to reduce burden of asthma on individuals and healthcare systems, are poorly and infrequently used (BTS/SIGN 2014). Studies show a mismatch between patients’ expectations and what professionals provide. (Ring <i>et al,<i> 2011).</i></i> <h3>Aim</h3> An exploration of health journeys of children with severe and recurrent wheeze: what makes a good management plan? <h3>Methods</h3> Purposeful sampling techniques were used to recruit patients. A convergent mixed-methods design, comprised of semi-structured interviews and notes review, was used. Data was analysed using inductive thematic analysis and descriptive statistics. <h3>Results</h3> Eleven children were recruited. Parents are motivated by symptoms and their own perceptions of wheeze to take action. They seek advice from multiple sources according to their own preferences, rather than symptom severity. The median number of admissions to A and E in the last two years was 3, and of GP consultations was 6.5; there was a negative correlation between these. Barriers to self-management include lack of knowledge, confidence and appropriate resources. Notably, healthcare professionals influenced the ability and willingness to self-manage by either empowering patients or providing paternalistic instruction. There was occasionally poor communication of agreed actions between primary and secondary care, which confused patients. Not all A and E attendances were noted in the GP system, and only one of 5 requests for GP follow-up was carried out. It was noted that patients see A and E as ‘specialist’ and may not follow-up with a ‘general’ physician upon discharge. Parents and children saw management plans as able to address key barriers. However, <i>no</i> notes in both GP and A and E mentioned providing a written plan. <h3>Conclusion</h3> Our data suggests the need to ‘nudge’ parents to self-manage before escalating appropriately by modifying existing management plans. Plans should be personalised, for example to target management of key triggers. Crucially, patients and both primary and secondary healthcare professionals must work together to implement mutually acceptable plans. We are using our data to create a mobile-based application which can be integrated into primary and secondary care, and is responsive to patients’ desires. Preliminary results show this will be well-received, and is perceived to be superior to paper-based plans.
P2.01-066 PD-L1 Tumor Expression and Its Effect on Overall Survival among Patients with Resected Non-Small Cell Lung Cancer (NSCLC)
Authors: Jane Sui, Min Yuen Teo, Shereen Rafee, Julie Mc Fadden, Kathy Gately, Martin Barr, Steven Gray, Sinead Cuffe, Stephen Finn
Journal: Journal of Thoracic Oncology (2017)
P3.01-043 Inhibition of Ornithine Decarboxylase Facilitates Pegylated Arginase Treatment in Lung Adenocarcinoma Xenograft Models
Authors: James Chung-Man Ho, U. Kin-Pong, Shi Xu, Paul Ning-Man Cheng, Sze Kwan Lam
Journal: Journal of Thoracic Oncology (2017)
P220 Determinants of inhaler adherence in a copd population
Authors: I Sulaiman, B Cushen, G Greene, J Seheult, D Seow, F Rawat, E MacHale, MC Mokoka, CN Moran, A Sartinin-Bhreathnach, S Tappuni, P MacHale, B Deering, M Jackson, H McCarthy, L Mellon, F Doyle, F Boland, RB Reilly
Journal: Thorax (2016)

<h3>Introduction</h3> Inhaler adherence in Chronic Obstructive Pulmonary Disease (COPD) is a crucial component of disease management with studies reporting relationships with both morbidity and mortality. The aim of this study was to identify determinants of inhaler adherence. <h3>Methods</h3> Over a 3-year period data was collected on 265 patients with COPD whose inhaler adherence was monitored for one month. Data on personal factors (i.e., cognition, anxiety and depression), disease severity and socioeconomic factors was collected. In addition, after one month of recruitment, information on exacerbations, re-admissions, quality of life, symptoms, self-reported adherence, beliefs in medicines and psychological status were collected. Inhaler adherence was calculated as a combination of timing of use, interval between doses and technique of use (Actual Adherence). <h3>Results</h3> At one month, patients who reported worse breathlessness (5 on the MRC Dyspnoea Scale) had worse Actual Adherence (p = 0.03). Interestingly, patients who had an exacerbation of their COPD within the month after recruitment had significantly lower Actual Adherence than those that didn’t (p = 0.01). In addition, patients with poorer cognition (p = 0.02), poorer cough PEFR (p &lt; 0.01) and more severe COPD (GOLD Stage IV, p = 0.05) had worse Actual Adherence. <h3>Conclusion</h3> In the large observational study of severe COPD patients, poor inhaler adherence was associated with worse symptoms, poorer cognition, more severe COPD and more exacerbations. This has significant implications for the long-term treatment of this patient population and may guide future interventions.
MA09.07 Phase I Trial of in situ Vaccination with CCL21 Gene-Modified DC Induces Specific Systemic Immune Response and Tumor Infiltrating CD8+ T Cells
Authors: Jay Lee, Mi-Heon Lee, Edward Garon, Jonathan W. Goldman, Felicita Baratelli, Dorthe Schaue, Gerald Wang, Frances Rosen, Jane Yanagawa, Tonya Walser, Ying Lin, Sharon Adams, Francesco Marincola, Paul Tumeh, Fereidoun Abtin, Robert Suh, Karen Reckamp, William Wallace, Gang Zeng, David Elashoff, Sherven Sharma, Steven Dubinett
Journal: Journal of Thoracic Oncology (2017)
Disease management and treatment of chronic myeloid leukemia (CML): Experience from the patient (pt) perspective.
Authors: T. W. Victor, M. Talpaz, A. Buzyn, C. B. Lemoine, A. Moadel, E. Olavarria, S. Leighton, S. Gupta, I. Hirji, C. C. Davis
Journal: Journal of Clinical Oncology (2011)

6606 Background: Over the last decade, BCR-ABL inhibitors have improved clinical prognoses of pts with CML. Few studies have evaluated attributes related to CML disease and treatment and their impact on pt management in a real-world setting. This study aims to understand the impact of CML disease and treatment on quality of life (QoL), treatment adherence, and daily productivity from the pt perspective. As CML usually requires long-term therapy, it is important to understand the value of minimizing symptoms and treatment burden. Methods: This ongoing cross-sectional study of 300 pts with CML (US, n=150; Europe, n=150), sourced from National Health and Wellness Survey and Lightspeed Research Chronic Illness Panel, is assessing pt experiences using validated questionnaires, including Short Form-12, MD Anderson Symptom Inventory, Work Productivity and Activity Impairment, Cancer Treatment Satisfaction Questionnaire, Patient Health Questionnaire (PHQ)-9, and pt-centric questions related to disease and treatment. CML treatment satisfaction (CTS) is assessed in a structural equation modeling framework using a maximum likelihood estimator and predictor variables from questions related to negative medication experience (composite measure of symptom occurrence, level of bothersome experience, and impact on daily activities). Standardized regression coefficients (betas) and p-values are used to evaluate CTS and pt experiences. Results: In a preliminary analysis of completed questionnaires from 75 US-based pts, median age was 49 years, 63% were female, and median time since diagnosis was 5 years (13% were within 12 months of diagnosis). Negative medication experience directly impacted CTS (beta = –0.40, p=0.001) suggesting treatment satisfaction decreased as level and impact of symptom burden increased. Most pts (95%) experienced bothersome symptoms including fatigue, diarrhea, bone pain, concentration/memory problems, and anxiety, which were reported as having most impact on normal daily routine. Conclusions: Initial findings suggest bothersome symptoms in these pts directly impact treatment satisfaction and normal daily routine. Data are being collected for the remaining cohort.
P1.03-027 Clinical and Histological Features Associated with SUV in FDG-PET-CT in Patients with Adenocarcinoma of the Lung
Authors: Amanda Tufman, Fiona Siokou, Ullrich Mueller-Lisse, Frank Berger, Kathrin Kahnert, Thomas Pfluger, Simone Reu, Julia Stump, Hauke Winter, Rudolf Huber
Journal: Journal of Thoracic Oncology (2017)
P2.02-015 Guideline Concordant Care is Associated with Better Survival for Patients with Stage III Non-Small Cell Lung Cancer
Authors: Hiba Ahmed, Yuan Liu, Kelli O'Connell, Theresa Gillespie, Maaz Ahmed, Pretest Patel, Rathi Pillai, Madhusmita Behera, Conor Steuer, Taofeek Owonikoko, Suresh Ramalingam, Walter Curran, Kristin Higgins
Journal: Journal of Thoracic Oncology (2017)
Complex Karyotypic Abnormalities Detected by Conventional Cytogenetic Analysis More Strongly Predict Survival Than FISH, ZAP70, or IgVH Mutation Status for Previously Treated Patients with CLL.
Authors: William G. Wierda, S. O’Brien, S. Faderl, A. Ferrajoli, G. Garcia-Manero, J. Burger, E. Schlette, L. Abruzzo, S. Lerner, M. Keating
Journal: Blood (2007)
Lenalidomide in Combination with Dexamethasone Is More Effective Than Dexamethasone at First Relapse in Relapsed Multiple Myeloma.
Authors: Edward Stadtmauer, Donna Weber, M. Dimopolous, Andrew Belch, Michel Attal, Miles Prince, Marta Olesnyckyj, Zhinuan Yu, Jerome Zeldis, Robert Knight
Journal: Blood (2006)
Immune Responses in AML Patients Following Vaccination with GRNVAC1, Autologous RNA Transfected Dendritic Cells Expressing Telomerase Catalytic Subunit hTERT.
Authors: John F. DiPersio, Robert H. Collins, William Blum, Marcel P Devetten, Patrick Stiff, Laurence Elias, Anita Reddy, Jennifer A. Smith, H. Jean Khoury
Journal: Blood (2009)
Phase I/II study of sapacitabine and decitabine administered sequentially in elderly patients with newly diagnosed acute myeloid leukemia.
Authors: F. Ravandi, S. Faderl, J. E. Cortes, G. Garcia-Manero, E. Jabbour, P. A. Boone, T. M. Kadia, G. Borthakur, W. G. Wierda, J. H. Chiao, H. Kantarjian
Journal: Journal of Clinical Oncology (2011)

6587 Background: Sapacitabine is a novel nucleoside analogue with a unique ability to cause irreparable single-strand DNA breaks and induce G2 cell cycle arrest. It is orally administered and has demonstrated promising activity in patients with acute myeloid leukemia (AML). In AML cell lines, the active metabolite of sapacitabine, CNDAC, is synergistic with hypomethylating agents with the synergy being more apparent if cells are treated with hypomethylating agents first. We are conducting a phase 1/ 2 study to evaluate the safety and efficacy of administering sapacitabine in alternating cycles with decitabine in elderly patients with newly diagnosed AML. Methods: Decitabine 20 mg/m2 is infused intravenously daily x 5 days of a 4-weeks cycle (odd cycles) alternating with sapacitabine 300 mg po b.i.d. x 3 days/week x 2 weeks of a 4-weeks cycle (even cycles). These doses are considered tolerable if dose limiting toxicity (DLT) occurs in ≤ 2 of 6 patients in the phase 1. The planned sample size for phase 2 is 24 patients including those who receiving the same doses of both drugs in the phase 1. The primary efficacy endpoint is response rate (CR, CRp, PR, or major HI). The regimen will be considered active if response rate is ≥ 30%. Eligible patients must be ≥70 years with untreated AML, unsuitable for or unwilling to receive standard induction chemotherapy; patients who received hypomethylating agents for prior MDS or MPD are excluded. Results: As of January 2011, 21 patients were treated with the above regimen and 16 had ≥ 60 days of follow-up. Median age is 76 years (range, 72-88). No DLT were observed. Three patients achieved CR, 2 PR and 1 major HI in platelets. Time to response is 2-4 cycles. Eight patients have received ≥ 4 cycles of treatment. Two patients died within 60-days and the deaths were unrelated to study drugs by investigator assessment. Common adverse events (regardless of causality) included weakness, anorexia, nausea, diarrhea, dehydration, dyspnea, edema, pneumonia, febrile neutropenia, neutropenia, thrombocytopenia, anemia, and hypocalcemia, mostly moderate in intensity. Conclusions: The sequential combination of decitabine and sapacitabine is safe and active in elderly AML.
P3.02b-108 Assessment of Clinical Usability of a cfDNA-Based Assay Detecting EGFR T790M Mutation in EGFR-TKI Refractory NSCLC Patients
Authors: Masaki Hanibuchi, Akira Kanoh, Takuya Kuramoto, Hisatsugu Goto, Atsuro Saijo, Hirokazu Ogino, Yasuhiko Nishioka
Journal: Journal of Thoracic Oncology (2017)
Combined Autophagy and Proteasome Inhibition for Multiple Myeloma: Preliminary Results of a Phase 1/2 Trial of Hydroxychloroquine and Standard Dose Bortezomib for Relapsed or Refractory Myeloma
Authors: Dan T. Vogl, Edward A. Stadtmauer, James E. Bradner, Lisa Davis, Martin Carroll, Charles W. Nichols, Doris Shank, Mary Carberry, Cezary R. Swider, Patricia A. Mangan, Brenda K. Shelly, Craig B. Thompson, Ravi K. Amaravadi
Journal: Blood (2008)
Hematopoietic Cell Transplant Co-Morbidity Index (HCTCI) and Multiple Myeloma (MM) Survival After Autologous Hematopoietic Cell Transplantation (AHCT)
Authors: Anuj Mahindra, Ayman A Saad, Mei-Jie Zhang, Xiaobo Zhong, Angela Dispenzieri, Amrita Krishnan, Sagar Lonial, Marcelo C Pasquini, Parameswaran Hari
Journal: Blood (2012)
Molecular Responses in Newly Diagnosed Chronic Myelocytic Leukemia (CML) Patients Treated with 800 mg Imatinib Daily: An Update from the RIGHT Trial Study Group.
Authors: Jorge Cortes, Francis Giles, August J. Salvado, Karen McDougall, Jerald Radich, Maher Albitar, Bayard L. Powell, Stuart Goldberg, Hagop M. Kantarjian
Journal: Blood (2006)
P277 Measuring sedentary behaviours in patients with idiopathic pulmonary fibrosis using wrist-worn accelerometers
Authors: CP Atkins, M Baxter, AP Jones, AM Wilson
Journal: Thorax (2016)

<h3>Introduction</h3> Idiopathic pulmonary fibrosis (IPF) patients suffer increasing functional limitation as the disease progresses. Increasing sedentary behaviour (SB) time has been associated with poorer health-related quality of life. Determining thresholds for activity vigour in patients with respiratory disease is difficult due to variability in cardiorespiratory limitations between individuals. SB time is not confounded by this limitation and may be a more reliable measurement of activity in patients with severe exercise limitation such as IPF. <h3>Methods</h3> Thirty-nine IPF patients wore a GENEActiv actiwatch continually for 7 days. Participants underwent measurement of forced vital capacity (FVC), diffusion capacity of carbon monoxide (DLCO), 6 minute walk distance (6MWD) <h3>Results</h3> Valid data was downloaded from 35 of the 39 participants (89.7%). Mean acceleration intensity recorded in the most active 5 hours of each day (M5; in milli-g) were 43.8 milli-g and time spent in SB was 551.7 minutes per day, higher than estimates of time in SB in similar age demographics in previous studies. Daily SB time correlated moderately with M5 values (pearson correlation −0.366, p = 0.030). Only M5 values predicted time in SB. No variability in SB time was seen by day of the week. There was a trend towards higher one and two year mortality with greater periods of time in SB. <h3>Conclusions</h3> Wrist-worn accelerometers reliably collected data and were well tolerated. IPF patients spent long periods of time in sedentary behaviours. Of the standard clinical measures used, 6MWD predicted daily activity but not SB time; no clinical measures predicted SB time. Increased time in SB may be associated with poorer outcomes in IPF patients; replacing time in SB with light activity may be a more achievable goal than increasing moderate or vigorous activity levels in IPF patients and improve outcomes.
P63 Salvage lung volume reduction surgery after failure or complications of endobronchial treatment with one-way valves for severe emphysema
Authors: R Bilancia, I Oey, P Perikleous, S Tenconi, D Waller
Journal: Thorax (2016)

<h3>Introduction</h3> Endobronchial lung volume reduction with one-way valves (ELVR), in combination with staged unilateral VATS lung volume reduction surgery (LVRS), multiplicates the options of treatment for emphysema. No experience has yet been reported in literature of the use of LVRS after failure of ELVR. We aimed therefore to review our current series. <h3>Methods</h3> 7 consecutive patients (3 male, age 68, 59–76) had successfull Chartis assessment and ELVR, and subsequently underwent salvage LVRS following failure or complications of primary procedure. All patients were suitable candidates for either approach according to our criteria (average RV/TLC 67 range 56–77, FEV1 32% range 25–38, DLCO 32%, range 24–55), with 4 patients classifying as moderate to high risk for LVRS and the rest as moderate or low. They were offered both options and opted for ELVR on the assumption of reduced risks and shorter hospitalisation. Valves were not removed prior to LVRS, except in one case who was also the first chronological patient in our series. <h3>Results</h3> Delayed collateral ventilation with no lobar collapse and no functional improvement at any time was observed in 3 patients. The remainder had lobar collapse with initial improvement: of these, 1 developed ipsilateral pneumothorax with persisting air leak leading to LVRS, 2 developed contralateral upper lobe compensatory hyperinflation (1R, 1L) and 1 ipsilateral lower lobe compensatory hyperinflation. No significant morbidity or 30-day/in-hospital mortality. Median lenght of stay after LVRS was 11 days (4–34), slightly longer (19 days, 4–34) for patients who were operated for contralateral hyperinflation or whose EBV was removed prior to VATS (no valve in situ on the operated side). Duration of drainage was also longer in these patients compared to the whole group, 18 (6–30) vs. 8 (5–30) days. Average EQ-5D score was 49.7 (18.9–71) six months after LVRS, vs. 42 (18.9–81.4) preoperatively, with only one patient reporting further deterioration. <h3>Conclusion</h3> ELVR can be considered as a trial of LVR not precluding salvage LVRS. Removal of endobronchial valves prior to surgery seems unnecessary and may actually be protective against excessive postoperative air leak. Occurrence of compensatory hyperinflation may suggest that single-stage bilateral ELVR could also be considered.